Finance Watch: Venture Rounds Trend Toward The High End

Larger Financings Dominate As Volume Rises

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Private Company Edition: First quarter data again confirm fewer but larger VC rounds in Q1. Big Q2 rounds include a $132.5m series C round for Endeavor Biomedicines, a $103m series A round for Reunion Neuroscience and Enlaza’s $100m series A.

Finance Watch Private Company
• Source: Shutterstock

The quarterly Venture Monitor report from Pitchbook and the National Venture Capital Association (NVCA) reported biopharma start-ups raised $5.9bn in the first quarter of 2024 – more than the sector raised during three out of the four quarters of 2023 and $1.1bn more than the industry raised in Q1 of last year. But with just 209 transactions and an average deal size of $28.2m, the number of companies that raised VC funding was the lowest since Q3 of 2018 when 202 companies raised $4.5bn, or $22.3m on average.

[Sidebar#SC150096]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.